Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple cholesterol punch: could three drugs beat two after a heart attack?

NCT ID NCT07508254

Disease control Sponsor: Punjab Institute of Cardology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a three-drug combination (atorvastatin, ezetimibe, and bempedoic acid) against the usual two-drug therapy for lowering LDL cholesterol in people who have had a heart attack or unstable angina. About 120 adults will take either the triple or dual therapy for 3 months. Researchers will measure how much their cholesterol drops and watch for any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atorvastatin, ezetimibe, and bempedoic acid (three cholesterol-lowering drugs)
What this could lead to
If it works, this could point toward a more effective way to lower cholesterol after a heart attack, potentially reducing the risk of future heart problems.
What could go wrong
This is a small, early-phase trial with only 120 participants, so results may not apply to everyone. The triple therapy may cause more side effects or not be significantly better than the standard dual therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Must be older than 18 years, male or female. 2. Diagnosis of ACS (Acute Coronary Syndrome) is confirmed when hospitalized. 3. Eligible for high-intensity statin therapy (atorvastatin) 4. Patients can provide written informed consent. 5. Patients will be eager to cooperate with study drugs and follow-up visits. Exclusion Criteria: 1. Intolerance or hypersensitivity to study drugs. 2. Liver or ALT/AST greater than three times the upper normal. 3. Renal dysfunction: estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m². 4. Gout with frequent bouts or severe hyperuricemia. 5. Pregnancy/lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndromes (ACS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndromes (ACS) Hypercholesterolemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Punjab Institute of Cardiology

    Lahore, Punjab Province, 56000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.